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7RESEARCH Open AccessDexmedetomidine versus standard care sedation
with propofol or midazolam in intensive care:
an economic evaluation
Heidi Turunen1*†, Stephan M Jakob2†, Esko Ruokonen3†, Kirsi-Maija Kaukonen4,5†, Toni Sarapohja1†,
Marjo Apajasalo1† and Jukka Takala2†Abstract
Introduction: Dexmedetomidine was shown in two European randomized double-blind double-dummy trials
(PRODEX and MIDEX) to be non-inferior to propofol and midazolam in maintaining target sedation levels in
mechanically ventilated intensive care unit (ICU) patients. Additionally, dexmedetomidine shortened the time to
extubation versus both standard sedatives, suggesting that it may reduce ICU resource needs and thus lower ICU
costs. Considering resource utilization data from these two trials, we performed a secondary, cost-minimization
analysis assessing the economics of dexmedetomidine versus standard care sedation.
Methods: The total ICU costs associated with each study sedative were calculated on the basis of total study
sedative consumption and the number of days patients remained intubated, required non-invasive ventilation, or
required ICU care without mechanical ventilation. The daily unit costs for these three consecutive ICU periods were
set to decline toward discharge, reflecting the observed reduction in mean daily Therapeutic Intervention Scoring
System (TISS) points between the periods. A number of additional sensitivity analyses were performed, including
one in which the total ICU costs were based on the cumulative sum of daily TISS points over the ICU period, and
two further scenarios, with declining direct variable daily costs only.
Results: Based on pooled data from both trials, sedation with dexmedetomidine resulted in lower total ICU costs
than using the standard sedatives, with a difference of €2,656 in the median (interquartile range) total ICU costs—
€11,864 (€7,070 to €23,457) versus €14,520 (€7,871 to €26,254)—and €1,649 in the mean total ICU costs. The median
(mean) total ICU costs with dexmedetomidine compared with those of propofol or midazolam were €1,292 (€747)
and €3,573 (€2,536) lower, respectively. The result was robust, indicating lower costs with dexmedetomidine in all
sensitivity analyses, including those in which only direct variable ICU costs were considered. The likelihood of
dexmedetomidine resulting in lower total ICU costs compared with pooled standard care was 91.0% (72.4% versus
propofol and 98.0% versus midazolam).
Conclusions: From an economic point of view, dexmedetomidine appears to be a preferable option compared
with standard sedatives for providing light to moderate ICU sedation exceeding 24 hours. The savings potential
results primarily from shorter time to extubation.
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Intensive care unit (ICU) costs can take up to 20% of
hospital budgets [1]. The daily costs of mechanically
ventilated patients may be 20% to 44% higher than those
of non-ventilated patients [2-5]. Therefore, shortening
the time to extubation and the duration of mechanical
ventilation (MV) are among key factors in reducing total
ICU resource utilization and the respective ICU costs.
Mechanically ventilated ICU patients are commonly
sedated to facilitate tolerance to artificial airway and
other interventions. Dexmedetomidine, a highly selective
alfa-2-agonist, was approved in Europe in 2011 for light
to moderate ICU sedation. Recent studies suggest that
dexmedetomidine may reduce the time to extubation
compared with standard sedation [6-8]. However, reduc-
tions in MV or length of stay in the ICU do not neces-
sarily always lead to cost savings [9-11]. Therefore, using
a cost-minimization approach [12], we aimed to evaluate
the net effect of dexmedetomidine on total ICU costs
and to compare it to sedation with propofol or midazo-
lam (or per cohort, a 1:1 mix of both, annually) in ICU
patients requiring prolonged MV in Europe.
Methods
Background and design of PRODEX and MIDEX
This is a secondary analysis based on resource utilization
and daily ICU cost data from two randomized, double-
blind, double-dummy trials of dexmedetomidine versus
standard sedation (midazolam in MIDEX and propofol
in PRODEX [8]) conducted in nine European countries.
In these two trials, mechanically ventilated adult patients
estimated to require sedation for at least a further
24 hours were randomly assigned in regard to study
sedative within 72 hours from ICU admission. Sedation
was monitored at least every 4 hours, and the drug infu-
sion rate was adjusted to achieve and maintain the tar-
geted light to moderate sedation levels; daily sedation
stops and spontaneous breathing trials were included.
Time to extubation was recorded. Duration of MV was
calculated from randomization until patients remained
free of any form of MV for 48 hours. Patients were
followed until ICU discharge or death or for a maximum
of 45 days. According to the protocol, this included
those patients who discontinued study medication pre-
maturely for any reason. The study protocols were ap-
proved by the ethics committees of the study centers/
countries (Additional file 1). Written informed consent
was obtained from the patient’s family, a legal represen-
tative, or both.
Summary of the economic analysis
In terms of maintaining patients at the target sedation
levels, the performance of dexmedetomidine was shown
in these trials to be non-inferior versus the standardsedatives, with no difference in mortality [8]. Therefore,
we chose to conduct a cost-minimization analysis [12],
focusing purely on the net impact of dexmedetomidine
on the costs of care.
The total ICU costs associated with each study seda-
tive were calculated on the basis of the total dose of the
study sedative consumed and the number of days each
patient remained intubated, required non-invasive venti-
lation (NIV), or required ICU care without MV. The
daily unit costs for the three consecutive ICU periods
were set to decline toward discharge [9-11] on the basis
of the observed reduction in mean daily TISS (Thera-
peutic Intervention Scoring System) points [13-15] be-
tween the periods. The resulting mean and median total
ICU costs were summarized per study sedative and com-
pared between groups. A base case analysis is presented,
followed by a number of sensitivity analyses to validate
the method.
Resource utilization parameters
First, for each patient with informed consent who had
received any study drug, we extracted the available ICU
resource utilization parameters from the original trial
data. These included the following: time to extubation,
duration of MV (including non-invasive MV), duration
of ICU stay, duration of total hospital stay, total consump-
tion of the assigned study sedative, and the daily number
as well as the cumulative sum of TISS points [13-15]
during the ICU stay. All of the above time periods were
defined to start from the point of randomization to study
drug.
We reflected the actual resources consumed as fol-
lows: if there was no record of the respective events hav-
ing commenced already, extubation or the end of MV or
ICU discharge or a combination of these was considered
to have taken place at the time of death or the move to
palliative care. Thus, compared with the original analysis
[8], the use of ‘worst ranking imputation’ was minimized
and applied only on the time-related end points of survi-
vors lost to follow-up or withdrawn from the study, if the
event had not yet taken place before that. This included,
for example, transferred patients, some of the patients
who had prematurely discontinued study medication and
for whom the relevant time points had not been captured,
and a few patients who withdrew from the entire trial be-
fore having reached the relevant time points. ‘Worst rank-
ing imputation’ implies that, whenever a time-related end
point was missing, it was assumed that the respective
event (for example, extubation/end of MV/ICU discharge,
usually following one another in this order) had taken
place at the next, actually recorded time point or, if no
such date was available, at 45 days.
When economic assessment of ICU care is performed,
it is inappropriate to use a single average daily ICU cost
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days over time needs to be taken into consideration to
quantify the actual costs for the patients [9-11]. To
enable this within our cost analysis, we further derived
from the above resource parameters three consecutive
ICU periods differing by ventilator use:
1. Time on invasive MV: (same as Time to extubation
in original trial data)
2. Time on NIV: (derived as Duration of MV-Time to
extubation)
3. Time off MV: (derived as Time from randomization
to actual ICU discharge-Duration of MV).
Unit cost assumptions
All trial sites (n = 78) were approached to define the ap-
plicable unit costs. Eventually, mean daily ICU costs
(total operative costs, including staff wages from the past
year, per bed day) were received from 18 trial centers,
resulting in a mean cost of €1,702 per ICU day. Specific
unit cost assumptions for each of these three ICU
periods were further set through adjusting the mean
daily ICU cost of the trial centers with TISS points—a
measure of resource utilization and nursing workload in
intensive care [13-15]. The daily TISS score typically
decreases from admission to discharge, reflecting the
diminishing need for ICU resources and interventions
over time, as the patient’s condition improves. A copy of
the scoring tool is available in Additional file 2.
In our pooled data of nearly 1,000 patients, the mean
differences in average daily TISS points were +33% for
days on invasive MV relative to days off MV and +26%
for days on NIV versus days off MV, indicating a de-
crease in resource needs as the need for MV is reduced
toward discharge. We therefore adjusted the mean daily
ICU cost of the 18 centers (€1,702 per day) for the three
ICU periods by using these observed relative differences.
The lowest unit cost, that for the off MV days (that also
are the last ICU days), was obtained through an iterative
process, in which the three period-specific unit costs
were set to such levels that the total ICU costs for the
entire pooled trial cohort remained the same whether
calculated with the single mean daily ICU cost of €1,702
or with the three period-specific unit costs. Thus, the
final base case unit cost assumptions for the present
analysis were the following:
Time on invasive MV: €1,850 per day (+33% versus
Day off MV)
Time on NIV: €1,750 per day (+26% versus Day off MV)
Time off MV: €1,390 per day.
Sedative acquisition costs were calculated by multiply-
ing the total study sedative dose consumed per patientwith the following unit costs (source: IMS Health,
Danbury, CT, USA): €0.012 per 1 mg propofol (equals
€12 per 1,000 mg vial), €0.160 per 1 mg midazolam
(€0.8 per 5 mg ampoule), and €0.090 per 1 μg dexmede-
tomidine (€18 per 200 μg ampoule of dexdor®; source:
Orion Pharma, Espoo, Finland).
Statistical methods
The data on resource utilization were analyzed by using the
non-parametric time-to-event (Gehan-Wilcoxon) test for
time to extubation, duration of MV, and actual ICU stay
until discharge. The Wilcoxon-Mann-Whitney test was
used for the cumulative sum of TISS points.
Costs were calculated on an individual patient basis. Both
mean (standard deviation) and median (interquartile range)
total ICU costs are given per treatment group throughout
the article. Unless otherwise indicated for a specific sensitiv-
ity analysis, the total ICU costs reported in the results in-
clude the study sedative acquisition costs. The distribution
of the total ICU costs is truncated and positively skewed.
Therefore, we applied the non-parametric bootstrapping
approach [16] to assess the likelihood of dexmedetomidine
resulting in lower total ICU costs versus the standard seda-
tives. In bootstrapping, the patient-level total ICU cost for
each study treatment group is resampled from the original
trial data 10,000 times (n = 1,000 per sample) and the differ-
ence in the total ICU costs is calculated for each iteration.
All analyses were performed by using SAS® 9.2 for Win-
dows (SAS Institute Inc., Cary, NC, USA).
Sensitivity analyses
To explore the robustness of the results, several one-way
sensitivity analyses were performed in the 1:1 pooled
data testing the impact of using more conservative unit
cost assumptions:
(S1) Cost of standard sedatives set to zero
(S2) Cost of dexmedetomidine increased to €22 per
200 μg (that is, €0.11 per 1 μg), representing the
current maximum dexdor® price for hospitals in
EU countries. The cost of providing NIV may vary
depending on how such care is organized in
practice. Therefore, we performed a sensitivity
analysis assuming a lower and a higher unit cost
for an ICU day on NIV:
(S3) Cost of ‘Time on NIV’ decreased to €1,390 per
24 hours (equals 24-hour cost in ICU off MV)
(S4) Cost of ‘Time on NIV’ increased to €1,850 per
24 hours (equals 24-hour cost in ICU on invasive MV).
We also conducted cost analyses:
(S5) including only the population with observed data
available from all three ICU periods, in order to
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and the imputations made on missing data
(S6) including only the patients of those 18 centers
which provided their ICU unit cost information
for this analysis.
(S7a-b) To further validate the main costing method in
our analysis, we used an alternative costing
approach based on the cumulative sum of daily
TISS points, so that the decrease in resource
needs, and thus indirectly in the unit cost for each
consecutive ICU day [9,10], is taken into
consideration on a day-by-day basis rather than in
three steps. In this analysis, the total cumulative sum
of the daily TISS points during the ICU stay was
multiplied by the unit cost of one TISS point, adding
sedative acquisition costs on top, to obtain the ‘Total
TISS-based ICU cost’ for each patient. First (S7a), a
unit cost of €40 per TISS point was assumed for the
analysis on the basis of the mean value of the
available information from 13 of the 18 PRODEX/
MIDEX study centers, which had provided also their
daily ICU cost information. The cost per TISS point
was available from fewer PRODEX/MIDEX study
centers and fewer countries than the cost per ICU
day used in the main costing method. Furthermore,
the costs of the four Estonian ICUs, among the 13
centers from three countries where the local cost
per TISS point was available, lowered the mean TISS
point cost disproportionally. Therefore, in the second
part of this analysis (S7b), we used an alternative unit
cost of €50 per point, corresponding to the three
daily ICU period-specific unit cost assumptions used
in the base case analysis (see ‘Unit cost assumptions’
section above).
(S8a-b) We explored two additional scenarios that
consider the declining direct variable daily ICU
costs only [9-11], assuming that they represent
either 25% [17,18] or 50% [18] of the total ICU
costs, as indicated by published European studies.
(S9) Finally, to reflect the net cost implications of
dexmedetomidine use in hospitals where the
underlying daily ICU costs are either much lower
or higher than in our base case, we also performed
an analysis in which the three period-specific mean
daily ICU unit costs were decreased or increased
to match mean costs between €500 and €3,100 per
any ICU day. This reflects a cost range somewhat
wider than found in the literature (that is, €700 to
€3,000 per day) [5,18-25]. Since the prices of the
standard sedatives can vary between hospitals, to
make the analysis more conservative toward
dexmedetomidine, the sedative acquisition costs
were set to zero for the standard sedatives but not
for dexmedetomidine.Results
Population
The pooled base case analysis consisted of 990 patients:
493 on dexmedetomidine and 497 on standard care. The
respective figures were 247/250 in MIDEX and 246/247
in PRODEX. For the majority of the patients, the main
reason for ICU admission was either medical or surgical
(70% and 22% in MIDEX and 55% and 30% in PRODEX,
respectively). Baseline demographics are similar to those
of the intention-to-treat population [8], as only eight
(0.8% of all) untreated or non-consenting patients were
excluded (see Additional file 3: Table S1 for further de-
tails on handling missing data).
Resource utilization
In this secondary economic analysis focusing on actual
costs of care, dexmedetomidine shortened the time to
extubation (P = 0.0003), the duration of total MV (P =
0.0052), and the duration of actual ICU stay (P = 0.0210)
compared with pooled standard sedation (Table 1). No dif-
ference in hospital ward stay after ICU discharge was ob-
served. For further details, see Additional file 4: Table S2.
ICU costs-base case analysis
Median total ICU costs were €2,656 lower with dexmede-
tomidine versus pooled standard care sedatives (Table 2).
The median costs with dexmedetomidine were €3,573
lower than midazolam and €1,292 lower than propofol
despite higher sedative acquisition costs (see Additional
file 5: Table S3 for sedative acquisition costs). Given the
bootstrapping analysis of the 1:1 pooled data, dexmedeto-
midine is likely to lead to lower total ICU costs than the
standard sedatives with a probability of 91.0% (Figure 1).
The same assessment conducted separately from the
PRODEX and MIDEX data sets indicated that, compared
with propofol, dexmedetomidine is likely to decrease the
total ICU costs with a probability of 72.4% but that the re-
spective likelihood in comparison with midazolam is
98.1%. For further details, see Additional file 6: Figure S1.
ICU costs-sensitivity analyses
Table 3 shows the results of the sensitivity analyses S1-S8
in the pooled data. The difference in the total ICU costs
observed in the base case analysis appeared to change only
little when the assumptions on sedative unit costs and cost
structures (the unit cost of NIV days) were varied. All vari-
ations in ICU unit costing (S1-S4) resulted in at least
€2,515 lower costs with dexmedetomidine on the basis of
median costs of each treatment group.
Sedation with dexmedetomidine resulted in lower ICU
costs in pooled population also when considering only
the patients (n = 757) with observed data available from
all three time periods (S5; with no imputations or cen-
soring) or only data (n = 336) from those study centers
Table 1 Resource utilization
1a. Time to extubation, hours P value
Mean (SD) Median (IQR)
Dexmedetomidine Standard care Dexmedetomidine Standard care
Pooled 166.1 (219.5) 195.1 (220.6) 89.0 (46.0-188.0) 118.0 (53.0-231.0) 0.0003
MIDEX 183.8 (226.4) 214.9 (229.3) 95.0 (59.0-212.0) 143.0 (75.0-232.0) 0.0013
PRODEX 148.3 (211.3) 175.1 (210.0) 69.0 (39.0-164.0) 91.0 (44.0-231.0) 0.0405
1b. Duration of mechanical ventilation, hours P value
Mean (SD) Median (IQR)
Dexmedetomidine Standard care Dexmedetomidine Standard care
Pooled 192.7 (241.1) 213.2 (229.1) 103.0 (51.0-215.0) 139.0 (70.0-265.0) 0.0052
MIDEX 199.2 (237.5) 231.4 (239.9) 115.0 (66.0-216.0) 146.5 (84.0-260.0) 0.0047
PRODEX 186.3 (245.0) 194.7 (216.7) 94.0 (45.0-211.0) 114.0 (47.0-266.0) 0.2049
1c. Duration of actual ICU stay, hours P value
Mean (SD) Median (IQR)
Dexmedetomidine Standard care Dexmedetomidine Standard care
Pooled 271.3 (267.2) 296.0 (265.6) 166.5 (98.5-315.0) 196.0 (116.0-361.0) 0.0210
MIDEX 281.8 (265.0) 318.4 (265.8) 179.5 (115.0-341.0) 217.0 (126.0-365.0) 0.0131
PRODEX 260.8 (269.6) 273.3 (265.0) 146.0 (94.0-293.0) 169.0 (93.0-355.0) 0.4057
1d. Cumulative sum of TISS points P value
Mean (SD) Median (IQR)
Dexmedetomidine Standard care Dexmedetomidine Standard care
Pooled 360 (375) 403 (360) 239 (152-426) 279 (177-503) 0.0030
MIDEX 353 (328) 419 (372) 239 (157-428) 300 (181-507) 0.0094
PRODEX 368 (419) 386 (347) 242 (139-421) 273 (170-501) 0.1064
Duration of ventilator use (1a-b), intensive care unit (ICU) stay (1c), and cumulative sum of Therapeutic Intervention Scoring System (TISS) points (1d) are derived
from MIDEX and PRODEX for the economic analysis. In MIDEX, the standard care sedative was midazolam; in PRODEX, it was propofol. IQR, interquartile range
(first to third); SD, standard deviation.
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further information in Additional file 7: Tables S4 and S5).
The complementary cost analysis based on TISS
points (S7, Table 3) indicated a difference of €1,448 (at
€40 per point) and €1,782 (at €50 per point, S7b) in me-
dian ICU costs, favoring dexmedetomidine over pooled
standard care (details in Additional file 8: Table S6).
When including only the declining, direct variable
daily costs in the cost comparison (S8a-b), dexmedeto-
midine resulted in lower median costs than pooled
standard care, the difference being €515 when variable
costs were assumed to represent 25% of the total costs
or €1,343 when assumed to be 50% (Table 3). Also, theTable 2 Total intensive care unit costs with dexmedetomidine
per patient
Mean (SD) Difference
in means, €Dexmedetomidine Standard care
Pooled 19,609 (19,568) 21,258 (19,298) −1,649
MIDEX 20,342 (19,412) 22,878 (19,483) −2,536
PRODEX 18,872 (19,735) 19,619 (19,008) −747
In MIDEX, the standard care sedative was midazolam; in PRODEX, it was propofol. IQsensitivity analyses comparing dexmedetomidine separ-
ately with propofol or midazolam indicated that dexmede-
tomidine sedation results in lower ICU costs (Additional
file 9: Tables S7 and S8).
A comparison of the total ICU costs of dexmedetomi-
dine and pooled standard care with different levels of
period-specific daily ICU costs (S9, Figure 2) indicated
that, even if the underlying mean daily ICU cost were as
low as €500, dexmedetomidine sedation would still re-
sult in lower total ICU costs than using the standard
sedatives. Naturally, if the unit costs are higher than in
the base case, the cost benefit of dexmedetomidine
increases.and current standard care sedatives, expressed as euros
Median (IQR) Difference in
medians, €Dexmedetomidine Standard care
11,864 (7,070-23,457) 14,520 (7,871-26,254) −2,656
12,871(8,126-25,147) 16,444 (8,955-27,676) −3,573
11,016 (6,781-21,696) 12,308 (6,787-25,247) −1,292
R, interquartile range; SD, standard deviation.
Figure 1 The likelihood of dexmedetomidine (D) to result in
lower total intensive care unit costs than pooled standard care
sedatives (SC), assessed by bootstrapping. As indicated by the
black circle, the likelihood that dexmedetomidine results in lower
total intensive care unit costs than the standard sedatives is 91.0%.
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This economic analysis suggests that the higher acquisi-
tion costs of dexmedetomidine compared with standard
sedation may be compensated for by reductions in other
ICU costs. In this study, dexmedetomidine resulted inTable 3 Sensitivity analyses S1-S8 in pooled data
Sensitivity analysis of the pooled data: dexmedetomidine versus stand
S1. Standard sedative cost set to zero
S2. Dexmedetomidine cost increased to €22 per 200 μg (€0.11 per 1 μg)
S3. Cost of a NIV day (24 hours) decreased to €1,390
S4. Cost of a NIV day (24 hours) increased to €1,850
S5. Patients with observed data from all three time periods (no censoring, no
N (dexmedetomidine): 366; N (standard care): 391
S6. Patients of those 18 study centers, from which the ICU unit costs were ob
N (dexmedetomidine): 170; N (standard care): 166
S7a. TISS-based total ICU costs, at unit cost of €40 per TISS point
S7b. TISS-based total ICU costs, at unit cost of €50 per TISS point
S8a. Only declining direct variable daily costs included, assuming they repres
S8b. Only declining direct variable daily costs included, assuming they repres
The impact of using alternative assumptions for the unit costs was tested. Addition
subpopulations and through applying a different type of costing method based on
System) points throughout the entire intensive care unit (ICU) stay with two differe
presented (8a-b). Further details of analyses S5-S8 can be found in Additional files 7lower ICU costs compared with standard care, primarily
by reducing the time to extubation. In economic evalua-
tions of ICU care, however, it is important to consider
the net impact on the total duration of ICU and hospital
stay [26]. In our analysis, dexmedetomidine reduced the
duration of total ICU stay compared with standard care,
without prolonging post-ICU ward stay. The finding of
reduced time to extubation is supported by the results of
the sensitivity analyses of the original studies [8] as well
as similar findings in previous studies [6,7,27].
The estimated unit costs and the assumption of less
expensive care after MV and ICU discharge are the key
drivers for the potential cost savings from dexmedetomi-
dine use. The unit cost assumptions were built on the
mean daily ICU costs obtained from 18 trial centers,
representing six out of nine study countries, and 34% of
all patients included in this economic analysis. However,
the intention of this study was not to calculate the pre-
cise costs for the specific ICUs who were involved in the
trials but rather to provide a more general picture of the
potential cost implications in different European set-
tings, where daily ICU costs may vary quite substantially
by country and center. In fact, the mean daily ICU cost
of the 18 study centers appears to be well in line with
the available cost references in the literature, indicating
an approximate ICU cost range of €700 to €3,000 per
day across Europe [5,18-25], a range that was well cov-
ered in the respective sensitivity analysis.
When an economic assessment of ICU care is per-
formed, a single mean daily ICU cost should not be
used; instead, the declining cost of ICU days over time
needs to be taken into consideration [9-11]. In the
present analysis, this was done in two different ways:
first, using three decreasing unit cost levels tied to theard care sedatives Difference in
mean costs, €
Difference in
median costs, €
−1,545 −2,515
−1,580 −2,591
−1,779 −2,717
−1,614 −2,551
imputation). −3,213 −2,462
tained. −1,763 −4,567
−1,499 −1,448
−1,926 −1,782
ent 25% of total ICU costs −256 −515
ent 50% of total ICU costs −720 −1,343
ally, cost difference between treatment groups was evaluated in two
the mean cumulative sum of daily TISS (Therapeutic Intervention Scoring
nt unit costs. Finally, two analyses including only direct variable costs are
, 8, and 9: Tables S4-8. NIV, non-invasive ventilation.
Figure 2 Impact of the underlying mean intensive care unit (ICU) daily cost level on the total ICU cost difference between dexmedetomidine
(D) and standard care (SC). The three ICU period-specific daily costs were varied up or down from the base case values that reflected an overall mean
cost of €1,702 per ICU day (triangle). Alternative period-specific unit costs reflecting a mean cost range between €500 and €3,100 per ICU day were
tested. Negative values indicate lower costs on dexmedetomidine. For a conservative approach, the standard sedative acquisition costs were set to zero.
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second, on a day-by-day basis, directly based on the
daily TISS points of each patient, thus reflecting mar-
ginal costs (sensitivity analysis) [9-11]. Both of these
costing approaches were driven by the daily decline in
variable costs toward discharge and indicated similar
results in favor of dexmedetomidine. The impact of mar-
ginal variable costs was given further consideration in
another sensitivity analysis assessing only the estimated
declining direct variable daily costs. Also, this analysis
supported the same conclusions.
In terms of methodology, we considered a direct
cost comparison based on consumed resources (cost-
minimization) to be appropriate as dexmedetomidine
has been shown to be non-inferior to standard care as
measured by the proportion of time patients are main-
tained at the targeted, light to moderate sedation levels
(Richmond Agitation and Sedation Scale: 0 to −3), without
a difference in mortality [8]. The chosen approach should
be considered to be conservative since it focuses purely on
resource consumption and costs. We assumed that dex-
medetomidine’s effectiveness, for which there is no simple
definition, is as good as that of the standard sedatives. Any
quality-of-life improvement that could potentially result
from earlier extubation, patient’s improved ability to com-
municate with the nursing staff [6,8], or reduced neuro-
cognitive adverse events [8] or delirium [6,28,29] were
thus overlooked in this analysis.
An alternative methodological approach focusing on net
costs could have been a cost-benefit analysis, in which not
only the sedative consumption but also the established dif-
ferences in the effectiveness of the treatment options areexpressed in monetary terms and compared against each
other resulting in ‘net monetary impact’ [12]. In this ap-
proach, resource utilization parameters, such as differ-
ences in time to extubation, duration of MV, and ICU
length of stay, would have been considered to be constitu-
ents of benefit, to which eventually a monetary value
would have been assigned. The result of such an analysis,
‘the net monetary benefit of dexmedetomidine’, would
have been equal to the difference in the total ICU costs
demonstrated in the present analysis, and thus the choice
of analysis would not have impacted the conclusion.
We did not include any specific extra costs for adverse
events. However, in a previous cost-minimization ana-
lysis of dexmedetomidine on the basis of the SEDCOM
(Safety and Efficacy of Dexmedetomidine Compared to
Midazolam) trial [6], such an approach was taken. In
that analysis, even when the costs due to differences in
adverse events were considered, dexmedetomidine was
still associated with median total ICU cost savings of
USD $9,679 compared with midazolam [30].
Since the scope of this analysis was economic, there
are some distinct differences in the definitions and hand-
ling of the length of stay parameters, compared with the
main clinical analysis [8]. In the present analysis, the
intention was to reflect the total ICU costs per treat-
ment group as realistically as possible, considering also
the potential administrative delays, availability of a suit-
able ward bed, and so on, which finally determined when
a patient actually got discharged. Therefore, the cost
calculation was based on the observed actual length of
ICU stay rather than the point ‘when medically fit for
ICU discharge’ [8]. Also, for non-survivors, the length of
Turunen et al. Critical Care  (2015) 19:67 Page 8 of 10ICU stay and the other relevant time points not yet
reached were censored at time of death, or when moving
to palliative care, as the accumulation of ICU costs
ceased. For most patients who discontinued study medi-
cation prematurely, the actual times of all of the three
relevant events had been captured as intended. In the
relatively small number of cases (22 of a total of 990 pa-
tients) in which the subsequent data were lost to follow-
up, the missing end points were worst ranked to the
next actually recorded time point or (if none was avail-
able) to 45 days. The same imputation principle was ap-
plied on the two study withdrawals that took place early
on, before MV or the ICU period had been completed.
Thus, no significant bias should be expected from the
way missing data were handled in this economic ana-
lysis. Nevertheless, since even non-significant imbalances
between the treatment groups in censoring or imput-
ation (or both) might introduce some degree of bias, we
performed a sensitivity analysis including only those pa-
tients for whom observed data were available from all of
the three ICU periods. Also, this analysis supported
similar conclusions as the base case.
As a relatively large share of the total ICU costs may
be of a fixed or at least semi-fixed nature [17,18], it may
not be straightforward to realize the full savings poten-
tial indicated by our analysis, at least in the short term.
However, even when only the direct variable ICU costs
were included, the analysis still indicated savings with
dexmedetomidine compared with standard care. Further-
more, from another perspective, even with the same staff
costs, dexmedetomidine may potentially have implications
for the cost-efficiency of the ICU, through freeing up beds
faster. For example, if the ICU stay was reduced from 8.2
to 6.9 days (30 hours) as in the present case, then the same
ICU staff could manage 19 additional patients per 100 pa-
tients sedated with dexmedetomidine, compared with
standard sedatives. In ICU units with shorter underlying
mean lengths of stay, the potential to increase the number
of treated patients is even larger. Whether such increased
patient turnover (and potentially a subsequently increased
third-payer compensation to the hospital) is realistic de-
pends on the organization and capacity of the referring
wards and on the subsequent step-down units’ ability to
admit the patients earlier.
The conclusion on the potential for cost savings with
dexmedetomidine vs. standard care was robust in all
sensitivity analyses performed. These included e.g. testing
the impact of several variations of the ICU daily unit
costs intended to represent different types of ICUs and
economies (or countries), with higher or lower under-
lying costs vs. our base case, two scenarios considering
the direct variable costs only, as well as a complementary
cost analysis based on a well-established ICU resource
use measure, the TISS points, collected daily in thePRODEX and MIDEX trials. In the analysis in which the
share of direct variable costs was assumed to be 25%
of the total ICU costs (which decline over time), the
marginal direct cost estimate for the last ICU days was
€347.50 (25% of €1,390 total cost of the Off MV days).
This is in line with the $397 estimate reported by Kahn
et al. [9] for the last ICU day and the $400 to $450
reported by Taheri et al. [11] for the marginal direct cost
of the last hospital day. Even this conservative variable
cost analysis still indicates that dexmedetomidine has the
potential for leading to lower costs.
There was a statistically significant reduction in the dur-
ation of MV as well as in the cumulative sum of TISS
points in comparison with midazolam or pooled standard
care but not in comparison with propofol. Nevertheless,
the likelihood of dexmedetomidine to result in lower total
ICU costs exceeded 90% compared with pooled standard
care and midazolam and was still relatively high (72%) even
when compared with propofol. The conclusion of our ana-
lysis is also supported by other similar findings regarding
lower resource use and ICU costs with dexmedetomidine
versus both midazolam [30,31] and propofol [32].
These results reflect a rather heterogenic, general ICU
patient population requiring prolonged sedation of over
24 hours. However, some relevant groups often requiring
prolonged sedation, such as patients with acute severe
neurological disorders, were excluded from the trials [8].
Furthermore, the reported cost savings were obtained
within a rigorously controlled clinical trial implementing
frequent sedation level control based on a validated sed-
ation scale, daily sedation interruption, and spontaneous
breathing trials. These interventions, recommended by
recent guidelines, may help avoid unnecessarily deep
sedation as such and are associated with improved out-
comes, including reduced MV and ICU stay [33-36]. In
practice, however, adherence to these best practices var-
ies largely between hospitals [37-40]. Therefore, the cost
consequences and impact of dexmedetomidine on ICU
cost-efficiency in different patient groups in a real-life
setting should be further assessed.
Conclusions
This analysis demonstrates that, when targeting light to
moderate sedation, dexmedetomidine represents an eco-
nomically sound option that may provide ICU cost sav-
ings compared with the standard sedatives, primarily
through reducing the time to extubation. If this can be
translated to a shorter ICU stay, more patients can be
managed with the same staff and fixed costs.
Key messages
 This analysis indicates that, from an economic point
of view, dexmedetomidine appears to be preferable
Turunen et al. Critical Care  (2015) 19:67 Page 9 of 10option for light to moderate intensive care unit
(ICU) sedation exceeding 24 hours.
 The potential of dexmedetomidine to achieve cost
savings versus standard sedatives is primarily due to
shorter time to extubation, which represents the
most resource-intensive period in the ICU. To some
extent, this benefit is also reflected in the total
duration of mechanical ventilation and ICU stay but
with higher uncertainty.
 From another perspective, these benefits may have
implications on ICU cost-efficiency by freeing the
ICU bed faster, allowing higher patient throughput
with the same staff and fixed costs.
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